BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Dong X, Liu F, Li M. Inhibition of nuclear factor κB transcription activity drives a synergistic effect of cisplatin and oridonin on HepG2 human hepatocellular carcinoma cells. Anticancer Drugs 2016;27:286-99. [PMID: 26704389 DOI: 10.1097/CAD.0000000000000329] [Cited by in Crossref: 15] [Cited by in F6Publishing: 9] [Article Influence: 2.5] [Reference Citation Analysis]
Number Citing Articles
1 Li B, Zhou B, Chen Y, Zhang X, Huang H. Signal-amplified detection of biomarker transcription factors with improved accuracy based on T4 DNA ligase protection and rolling circle amplification. Sensors and Actuators B: Chemical 2022;360:131598. [DOI: 10.1016/j.snb.2022.131598] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Hua X, Wu P, Gao GS, Ye XL. Combination of oridonin and TRAIL induces apoptosis in uveal melanoma cells by upregulating DR5. Int J Ophthalmol 2021;14:1834-42. [PMID: 34926196 DOI: 10.18240/ijo.2021.12.05] [Reference Citation Analysis]
3 El-Baba C, Baassiri A, Kiriako G, Dia B, Fadlallah S, Moodad S, Darwiche N. Terpenoids' anti-cancer effects: focus on autophagy. Apoptosis 2021. [PMID: 34269920 DOI: 10.1007/s10495-021-01684-y] [Reference Citation Analysis]
4 Li X, Zhang CT, Ma W, Xie X, Huang Q. Oridonin: A Review of Its Pharmacology, Pharmacokinetics and Toxicity. Front Pharmacol 2021;12:645824. [PMID: 34295243 DOI: 10.3389/fphar.2021.645824] [Reference Citation Analysis]
5 Li X, Chen W, Liu K, Zhang S, Yang R, Liu K, Li D, Huang Y. Oridonin Sensitizes Hepatocellular Carcinoma to the Anticancer Effect of Sorafenib by Targeting the Akt Pathway. Cancer Manag Res 2020;12:8081-91. [PMID: 32982405 DOI: 10.2147/CMAR.S257482] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
6 Liu X, Xu J, Zhou J, Shen Q. Oridonin and its derivatives for cancer treatment and overcoming therapeutic resistance. Genes Dis 2021;8:448-62. [PMID: 34179309 DOI: 10.1016/j.gendis.2020.06.010] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
7 Yu L, Xu H, Zhang S, Chen J, Yu Z. SDC1 promotes cisplatin resistance in hepatic carcinoma cells via PI3K-AKT pathway. Hum Cell 2020;33:721-9. [PMID: 32314115 DOI: 10.1007/s13577-020-00362-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
8 Liu D, Qin H, Yang B, Du B, Yun X. Oridonin ameliorates carbon tetrachloride-induced liver fibrosis in mice through inhibition of the NLRP3 inflammasome. Drug Dev Res 2020;81:526-33. [PMID: 32219880 DOI: 10.1002/ddr.21649] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 6.0] [Reference Citation Analysis]
9 Xing F, Sun C, Luo N, He Y, Chen M, Ding S, Liu C, Feng L, Cheng Z. Wogonin Increases Cisplatin Sensitivity in Ovarian Cancer Cells Through Inhibition of the Phosphatidylinositol 3-Kinase (PI3K)/Akt Pathway. Med Sci Monit 2019;25:6007-14. [PMID: 31402794 DOI: 10.12659/MSM.913829] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
10 Chen Y, Jia Y, Song W, Zhang L. Therapeutic Potential of Nitrogen Mustard Based Hybrid Molecules. Front Pharmacol 2018;9:1453. [PMID: 30618747 DOI: 10.3389/fphar.2018.01453] [Cited by in Crossref: 23] [Cited by in F6Publishing: 18] [Article Influence: 5.8] [Reference Citation Analysis]
11 Xu J, Wold EA, Ding Y, Shen Q, Zhou J. Therapeutic Potential of Oridonin and Its Analogs: From Anticancer and Antiinflammation to Neuroprotection. Molecules 2018;23:E474. [PMID: 29470395 DOI: 10.3390/molecules23020474] [Cited by in Crossref: 36] [Cited by in F6Publishing: 33] [Article Influence: 9.0] [Reference Citation Analysis]